You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ritonavir

Showing 26 - 50 of 1,309
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COVID-19 Trial in Jinan (QLS1128 A-Dose 1~5 and Ritonavir, QLS1128 C-Dose 1~3 and Ritonavir, QLS1128 D-Dose 1 and Ritonavir)

Recruiting
  • COVID-19
  • QLS1128 A-Dose 1~5 and Ritonavir
  • +2 more
  • Jinan, Shandong, China
    Qilu Pharmaceutical Co., Ltd.
Jul 11, 2022

Chronic Hepatitis Delta Trial run by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (Peginterferon

Not yet recruiting
  • Chronic Hepatitis Delta
  • Peginterferon Lambda
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 25, 2023

Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma Trial in Rochester (drug, genetic, other)

Withdrawn
  • Hodgkin Lymphoma
  • +4 more
  • Rochester, Minnesota
    Mayo Clinic
Nov 28, 2022

COVID-19 Trial in London (Favipiravir, Lopinavir/ Ritonavir, Favipiravir Placebo)

Completed
  • COVID-19
  • London, United Kingdom
  • +1 more
Dec 12, 2022

Healthy Trial in Cairo (Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose), Nirmatrelvir 150 mg + Ritonavir 100 mg

Recruiting
  • Healthy
  • Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)
  • +2 more
  • Cairo, Egypt
    Genuine Research Center GRC
Aug 4, 2022

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19

Completed
  • Coronavirus
  • +2 more
  • Doha, Qatar
    Hamad Medical Corporation
Aug 15, 2022

COVID-19 Trial (SSD8432 300mg, SSD8432 750mg, SSD8432Placebo)

Not yet recruiting
  • COVID-19
  • SSD8432 300mg
  • +2 more
  • (no location specified)
May 23, 2022

COVID-19 Trial (SSD8432 750mg, SSD8432 )

Not yet recruiting
  • COVID-19
  • SSD8432 750mg
  • SSD8432 placebo
  • (no location specified)
May 17, 2022

COVID-19 Patients Trial in Shenzhen (SSD8432 dose 1/Ritonavir, SSD8432 dose 2/Ritonavir)

Recruiting
  • COVID-19 Patients
  • SSD8432 dose 1/Ritonavir
  • SSD8432 dose 2/Ritonavir
  • Shenzhen, Guangdong, China
    Shenzhen Third People's Hospital
May 14, 2022

Safety Issues Trial in Shanghai (Nirmatrelvir and ritonavir stage 1, Nirmatrelvir and ritonavir stage 2)

Completed
  • Safety Issues
  • Nirmatrelvir and ritonavir stage 1
  • Nirmatrelvir and ritonavir stage 2
  • Shanghai, Shanghai, China
    Department of Nephrology, Renji Hospital, Shanghai JiaoTong Univ
Jun 12, 2022

Healthy Participants Trial in Hollywood (Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran)

Completed
  • Healthy Participants
  • Hollywood, Florida
    Research Centers of America ( Hollywood )
Jan 18, 2022

Healthy Participants Trial in Brussels (Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam)

Completed
  • Healthy Participants
  • Brussels, Bruxelles-capitale, Région DE, Belgium
    Brussels Clinical Research Unit
Jan 18, 2022

COVID-19 Trial in United States (Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir)

Not yet recruiting
  • COVID-19
  • Miami, Florida
  • +2 more
Jul 21, 2022

HIV-1 Infections Trial in Worldwide (Darunavir, Ritonavir)

Completed
Has Results
  • HIV-1 Infections
  • Rio De Janeiro, Brazil
  • +16 more
Oct 6, 2022

HIV Trial in Cincinnati (darunavir, ritonavir, rosuvastatin, rosuvastatin, darunavir, ritonavir)

Completed
Has Results
  • HIV Infections
  • darunavir, ritonavir, rosuvastatin
  • rosuvastatin, darunavir, ritonavir
  • Cincinnati, Ohio
    University of Cincinnati AIDS Clinical Trials Unit
Jan 19, 2022

Chronic Hepatitis c Genotype 1 Trial in Moscow, Saint Petersburg (Narlaprevir, Ritonavir, Sofosbuvir)

Completed
  • Chronic Hepatitis c Genotype 1
  • Moscow, Russian Federation
  • +4 more
Oct 27, 2022

Healthy Participants Trial in Shanghai (PF-07321332/ritonavir)

Completed
  • Healthy Participants
  • Shanghai, Shanghai, China
    Huashan Hospital,Fudan University
Jun 28, 2022

Healthy Participants Trial in New Haven (PF-07321332/ritonavir, Ritonavir)

Completed
  • Healthy Participants
  • New Haven, Connecticut
    New Haven Clinical Research Unit
Feb 15, 2022

COVID-19 Trial (SIM0417, Placebo)

Not yet recruiting
  • COVID-19
  • (no location specified)
Aug 17, 2022

Bioavailability Trial in New Haven (PF-07321332/ritonavir, PF-07321332)

Completed
  • Bioavailability
  • New Haven, Connecticut
    New Haven Clinical Research Unit
Jun 28, 2022

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised Trial

Not yet recruiting
  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
  • +4 more
  • Cooperstown, New York
  • +10 more
Dec 11, 2022

COVID-19 Trial (PF-07321332 (nirmatrelvir)/ritonavir)

Not yet recruiting
  • COVID-19
  • PF-07321332 (nirmatrelvir)/ritonavir
  • (no location specified)
Aug 2, 2022

COVID-19, Immunodeficiency Trial (Paxlovid 5 days, Paxlovid 10 days, Tixagevimab and Cilgavimab)

Not yet recruiting
  • COVID-19
  • Immunodeficiency
  • Paxlovid 5 days
  • +2 more
  • (no location specified)
Oct 18, 2022

HIV-1 Trial (Doravirine, Darunavir, Ritonavir)

Active, not recruiting
Has Results
  • HIV-1
  • (no location specified)
Aug 19, 2022

Healthy Participants Trial in Jinan (SSD8432 dose 1~7 and Ritonavir, SSD8432 dose 8~9, SSD8432 dose 10~12 and ritonavir)

Recruiting
  • Healthy Participants
  • SSD8432 dose 1~7 and Ritonavir
  • +4 more
  • Jinan, Shandong, China
    The First Affiliated Hospital of Shandong First Medical Universi
Apr 15, 2022